The Society of Nuclear Medicine and Molecular Imaging
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed biochemically recurrent prostate cancer, with original diagnosis no more than 2 years from date of consent.
Intermediate unfavorable or high-risk prostate cancer.
All patients under consideration for radiation therapy, either at the time of first recurrence or in salvage radiation therapy will be included.
Patients who have started bicalutamide up to a maximum of 3 days prior to randomization will be allowed to be on protocol. Otherwise, a washout period of at least 42 days will be required.
Biological males, at least 18 years of age.
Prostate specific antigen (PSA) \< 1.0 ng/mL.
Agreement to adhere to Lifestyle Considerations throughout study duration
Ability to understand and willingness to sign an IRB approved written informed consent document.
You may not be if
Patients currently on androgen deprivation therapy (ADTs).
Currently receiving any other investigational agents.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to POSLUMA, furosemide, bicalutamide, or other agents used in the study.
